Sugi Predict

Sugi Predict / Compounds / SCHEMBL17439216

SCHEMBL17439216

SCHEMBL17439216

CC(=O)N(C)c1cc(Br)ccn1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.46
▸ KDM4E B2RXH2 4/20 0.46
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ HCRTR1 O43613 1/20 0.37
▸ HCRTR2 O43614 1/20 0.37
▸ BUB1 O43683 1/20 0.36
▸ LMNA P02545 2/20 0.36
▸ POLB P06746 2/20 0.36
▸ BRD4 O60885 1/20 0.35
▸ FSCN1 Q16658 1/20 0.35
▸ ELANE P08246 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ NCEH1 Q6PIU2 1/20 0.33
▸ GRM5 P41594 1/20 0.32
▸ SORT1 Q99523 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30731261 1.00 ALDH1A1 (0.46) ALDH1A1KDM4ESMN1; SMN2HCRTR1HCRTR2
SCHEMBL3475222 0.86 ALDH1A1 (0.50) ALDH1A1KDM4ESMN1; SMN2HCRTR1HCRTR2
SCHEMBL31143251 0.81 ALDH1A1 (0.42) ALDH1A1KDM4ESMN1; SMN2HCRTR1HCRTR2
SCHEMBL21713884 0.81 ALDH1A1 (0.44) ALDH1A1KDM4ESMN1; SMN2HCRTR1HCRTR2
SCHEMBL18133753 0.80 RAB9A (0.48) ALDH1A1KDM4ESMN1; SMN2BUB1FSCN1
SCHEMBL16904543 0.79 USP30 (0.42) ALDH1A1KDM4ESMN1; SMN2HCRTR1HCRTR2
SCHEMBL29187152 0.79 OPRD1 (0.39) ALDH1A1KDM4ESMN1; SMN2BUB1POLB
SCHEMBL163629 0.78 KDM4E (0.46) ALDH1A1KDM4ESMN1; SMN2HCRTR1HCRTR2
SCHEMBL12678539 0.78 SSTR4 (0.40) ALDH1A1KDM4ESMN1; SMN2HCRTR1HCRTR2
SCHEMBL29580743 0.78 SSTR4 (0.40) ALDH1A1KDM4ESMN1; SMN2HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 — — EP disclosed
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2024-03-05 — — US disclosed
CN-112088157-B Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors 拉文纳制药公司 2023-12-26 — — CN disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 — — US disclosed
CN-115484948-A Compound and use thereof 福宏治疗公司 2022-12-16 — — CN disclosed
EP-4096657-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 — — EP disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 — — EP disclosed
EP-2920183-B1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS GLAXOSMITHKLINE LLC (US) 2017-03-08 — — EP disclosed
EP-2920183-B1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS GLAXOSMITHKLINE LLC (US) 2017-03-08 — — EP disclosed
US-20160297832-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS GLAXOSMITHKLINE LLC 2016-10-13 — — US disclosed
US-20160297832-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS GLAXOSMITHKLINE LLC 2016-10-13 — — US disclosed
US-20160297832-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS GLAXOSMITHKLINE LLC 2016-10-13 — — US disclosed
WO-2016022312-A1 HETEROCYCLIC KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-02-11 — — WO disclosed
WO-2016022312-A1 HETEROCYCLIC KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-02-11 — — WO disclosed
US-20160016966-A1 FUROPYRIDINES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-01-21 — — US disclosed
US-20160016966-A1 FUROPYRIDINES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-01-21 — — US disclosed
US-20160016966-A1 FUROPYRIDINES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-01-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB ALDH1A1 2571/4885KDM4E 1848/4885SMN1; SMN2 40/4885
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB ALDH1A1 2571/4885KDM4E 1848/4885SMN1; SMN2 40/4885
US-20160297832-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS BRD4, BET1, BRD3 ALDH1A1 2234/4885KDM4E 226/4885SMN1; SMN2 2089/4885
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors PIP5K1A, PIP5K1B, PIP5K1C ALDH1A1 4524/4885KDM4E 774/4885SMN1; SMN2 3679/4885
US-20160016966-A1 FUROPYRIDINES AS BROMODOMAIN INHIBITORS BRD3, BRD4, BRPF3 ALDH1A1 2372/4885KDM4E 1566/4885SMN1; SMN2 4110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.